-
Recent Posts
- Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) Spikes with Promise of Tasimelteon
- Is Enviro-Serv, Inc. (PINKSHEETS: EVSV) Any Closer to Generating Revenues?
- Eagle Bulk Shipping, Inc. (NASDAQ: EGLE) Spikes on Earnings but is there More to the Numbers?
- Is Gold in the Future for FBC Holding, Inc. (OTCQB: FBCD)?
- Will it be Clear Sailing for Alas International Holdings, Inc. (PINKSHEETS: VDSC)?
Categories
OTC Equity Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
Tags
aapl advertising alternative energy amex apple basic materials biopharmaceutical biotechnology cancer capital goods cloud computing copper drilling energy energy stocks exploration facebook fda fda approval gas gold gold mining google healthcare stocks investors ipad iphone mining NASDAQ natural gas nyse oil oil and gas otcbb penny stock penny stocks petroleum pharmaceutical pinksheets Pink Sheets s silver sprint stocks tradingSite
OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.
Registration to our newsletter is FREE, Join today by entering your email below!
Tag Archives: clinical trial
Can Itonis, Inc. (PINKSHEETS: ITNS) Bring Over-the-Counter and Prescription Homeopathic Nasal Spray for the Treatment of Nausea to Market?
Itonis, Inc. (PINKSHEETS: ITNS) has put together their second straight day of heavy trading volume following Monday’s announcement that Itonis Pharmaceuticals, a division of ITNS, had commenced the organization of the first clinical trial of their recently announced over-the-counter and … Continue reading
Posted in Uncategorized
Tagged clinical trial, cold remedy, drugs, investors, itns, itonis inc, nasal spray, pharma, prescription
Leave a comment
Is PolyMedix, Inc. (OTCBB: PYMX) Playing a Familiar Song with Positive Outlook for Brilacidin?
For those investors who have held or are currently holding shares of PolyMedix, Inc. (OTCBB: PYMX) the old proverb “Fool me once shame on you. Fool me twice shame on me” may serve as a valuable reminder that the biotechnology … Continue reading
Posted in Uncategorized
Tagged absssi, brilacidin, clinical trial, fda, heparin, hypotension, investors, phase ii, polymedix, pymx
Leave a comment
Exelixis, Inc. (NASDAQ: EXEL) Remains a Big Risk Big Reward Biotech with Everything Riding on Cancer Drug Cabozantinib
It’s possible that the climb back north may have started for Exelixis, Inc. (NASDAQ: EXEL) as the biotechnology company is now in recovery mode following yesterday’s poor performance. On Wednesday shares of EXEL sank as low as 4.27 as investors … Continue reading
Posted in Articles, NASDAQ
Tagged biotech, cabozantinib, cancer, clinical trial, exel, exelixis, fda, investors, lung, mcrpc, sanofi
Leave a comment
Viral Genetics Inc. (PINKSHEETS: VRAL) Advancing from Preclinical to Clinical-Stage Company with Potential Ovarian Cancer Treatment Developed from MDT Platform
One day after Viral Genetics Inc. (PINKSHEETS: VRAL) announced that the physician-initiated Investigational New Drug (P-IND) application submitted to the FDA in late April, 2012 had cleared the FDA’s screening process, paving the way for the small biotechnology company to … Continue reading
Posted in Uncategorized
Tagged cancer treatment, clinical trial, drug, fda, investors, mdt, ovarian cancer, penny stocks, viral genetics, vral
Leave a comment
CEL-SCI Corporation Inching Closer Toward Phase III Clinical Trial of Multikine but Investors Remain Skeptical
It’s hard to image a biotechnology company entering a Phase III clinical trial to test an immunotherapy for head and neck cancer would be trading in the 0.68 – 0.71 range but that is exactly where CEL-SCI Corporation (AMEX: CVM) … Continue reading
Posted in AMEX, Articles
Tagged amex, biotechnology, cancer, cel-sci, clinical trial, cvm, fda, investors, multikine, penny stocks, phase iii
Leave a comment


